Novavax Inc (NVAX)

R&D to Revenue

124.68%

Quarterly · Period ending:

NVAX logo

NVAX R&D to Revenue

Latest reported124.68%
NVAX Quarterly R&D/Revenue (800.00% → 124.68%)
High-resolution chart · PNG

NVAX r&d to revenue history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Novavax Inc R&D to Revenue — Quarterly
Period endingR&D to Revenue
124.6834%
68.4318%
50.2763%
139.5046%
32.4498%
13.3408%
118.1959%
103.138%
25.7401%
98.747%
56.5305%
481.4585%
51.711%
-3,844.135%
89.5854%
41.4248%
155.7875%
63.4202%
-132.5458%
228.2408%
191.4941%
132.5207%
143.4601%
187.2879%
98.0528%
500.2961%
332.8153%
742.3614%
906.0769%
890.8338%
708.585%
534.2728%
413.4596%
461.1416%
476.9209%
501.2213%
583.2294%
662.9225%
946.4716%
1,639.8329%
2,590.978%
1,634.7084%
1,296.8221%
427.8467%
178.9225%
262.1039%
453.5247%
233.9786%
184.0659%
194.5591%
186.5455%
290.4623%
305.4376%
246.0736%
206.1323%
110.928%
72.8706%
109.371%
11.0864%
124.5807%
186.0713%
649.1607%
9,423.5294%
4,497.1429%
90,385.7143%
8,208.1818%
14,812.1622%
2,614.9254%
18,265.5172%
20,314.2857%
8,378.5714%
4,461.3402%
1,573.0994%
968.1223%
-653.8951%
428.4411%
2,653.7975%
547.7545%
236.8694%
243.3361%
405.3635%
155.9478%
58.6453%
62.1853%
59.4816%
127.027%
75.3177%
237.6723%
40.8985%
94.6273%
57.9298%
59.8267%
122.7253%
198.0737%
97.2925%
150.0608%
67.5448%
48.277%
42.3247%
34.875%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.